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Conclusions The burden of GHD in children and ado-
lescents is considerable and not limited to short stature. 
The severity of GHD impact on children and adolescents 
appears to be variable and individualized, but these data 
indicate that early identification and growth hormone treat-
ment may lead to fewer impacts.
Keywords Growth hormone deficiency · Burden of 
illness · Patient experience · Patient-reported outcomes
Introduction
Growth hormone deficiency (GHD) results when the pitui-
tary gland does not produce enough growth hormone to 
stimulate the body to grow and manifest as a slow or flat 
rate of growth in both early and later childhood [1]. Chil-
dren with GHD usually have typical body proportions, but 
are often chubbier, shorter, and may be perceived to be 
younger than their age when compared with peers of the 
same age and gender [2, 3]. The prevalence of childhood 
GHD reported in published studies is within the range 
1.8–2.9 per 10,000 in Europe and US [4–6]. A recent study 
reported the incidence of childhood onset GHD to be 2.58 
for males and 1.70 for females per 100,000 [7]. The cause 
of most childhood onset GHD is not known (idiopathic) [1] 
or can be genetic or syndromic (developed in utero); it can 
also develop as the result of an injury or medical condition 
such as head trauma or brain tumor [1].
Children with GHD may exhibit psychological and 
behavioral impacts. Although some of these impacts may 
be directly related to short stature, there are additional 
proximal impacts which are not directly related to short 
stature such as academic underachievement due to poor 
concentration [8]. In fact, improvement in height alone is 
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not necessarily sufficient to improve quality of life (QoL) 
for GHD children as compared to improvements in QoL for 
children with idiopathic short stature [9]. Unfortunately, 
although there are measures of the impact of short stature, 
no disease-specific measures currently exist which assesses 
the impact of GHD on children and adolescents. The pur-
pose of this study was to examine the burden of GHD on 
children and adolescents and to conduct concept elicitation 
to develop a model of the impact of GHD with adequate 
conceptual validity to support the development of disease-
specific patient-reported outcome (PRO) and observer-
reported outcome (ObsRO) measures.
Methods
Focus groups and interviews with children, ages 8 to <13 
years, diagnosed with GHD and parents of children, ages 
≥4 to <13 years, diagnosed with GHD were conducted in 
Germany, the United Kingdom (UK), and the United States 
(US). Both focus groups and individual interviews are 
acceptable methodologies to collect qualitative data with 
children approximately aged 8 or older [10] as well as with 
adults. However, as it was expected, given the challenges 
of recruiting children with GHD, that it could be difficult 
to recruit sufficient numbers of interviewees in any given 
location for focus groups, the methodology used in each 
country was determined by the geographic distribution of 
the respondents. Focus groups conducted with children 
were divided by gender (one for boys, and one for girls) and 
for child telephone interviews, the child was asked if they 
preferred a gender-matched interviewer. A purposive sam-
pling method was used for both focus group and interview 
selection. This study was conducted from April 2014 to 
March 2015 and was approved by the Western Institutional 
Review Board (WIRB tracking #20140677).
Child respondents were eligible if they met the follow-
ing criteria: (1) pre-pubertal, ages 8 to <13 years with a 
diagnosis of isolated Growth Hormone (GH) deficiency, 
GH deficiency as part of multiple pituitary hormone defi-
ciencies, or organic GH deficiency; (2) diagnosed with 
GHD as defined by a maximum stimulated GH < 10 ng/mL 
(μg/L) on two separate stimulation tests performed either 
on the same day or on two separate days, OR one stimula-
tion test performed along with an IGF-1 test resulting in a 
maximum stimulated GH < 10 ng/mL (μg/L) and an IGF-1 
level two standard deviations below the mean reference 
range for age and gender; (3) negative signs for intracra-
nial tumor or tumor growth, OR if GH deficiency occurred 
after treatment for any brain tumor, the patient has to be at 
least one year in clinical remission; (4) currently receiving 
any prescription GH treatment for no more than 12 months, 
or never treated with growth hormone. Parent/guardian 
respondents were eligible if their child met the diagnostic 
and medical criteria noted above; however, the age of their 
child could be any age under 13 years. Additionally, par-
ent respondents were required to live in the same residence 
as the child with GHD and be able to provide information 
on the child’s GHD and treatment as well as report on the 
child’s observed behavior.
Child and parent respondents were excluded from the 
study if the child had (1) any clinically significant abnor-
mality likely to affect growth or the ability to evaluate 
growth, such as, but not limited to, chronic diseases like 
renal insufficiency, spinal cord irradiation, and malnu-
trition; (2) overt diabetes mellitus (fasting blood sugar 
>126  mg/dl) and impaired fasting sugar (fasting blood 
sugar >100 mg/dl after repeated blood analysis); (3) chro-
mosomal abnormalities and medical syndromes (Turner’s 
syndrome, Laron syndrome, Noonan syndrome, or absence 
of growth hormone receptors), with the exception of septo-
optic dysplasia; (4) congenital abnormalities (causing skel-
etal abnormalities), Russell–Silver syndrome, and skeletal 
dysplasia.
Three recruitment strategies were employed. First, eli-
gible child and adolescent patients were identified by phy-
sicians from their current patient caseload. The physician 
or designated staff person contacted the parent/guardian 
of eligible patients to determine their, and/or their child’s, 
interest in the study. Once permission to share their interest 
was received, this information was forwarded to the study 
coordinators who continued the recruitment process. For 
the second strategy, national and international GHD-related 
advocacy and support organizations posted recruitment 
information on their discussion and social media sites, 
providing contact information for the study for interested 
respondents. Lastly, respondents were identified by pro-
fessional research organizations, either through physician 
referrals or from their patient panels. These organizations 
contacted individuals enrolled in their proprietary data-
bases and prequalified them by telephone using a screen-
ing script. For anyone who was recruited outside of a clini-
cal setting, evidence of diagnosis was obtained by a signed 
letter from their physician providing confirmation that the 
respondent met all eligibility requirements. There were tar-
get quotas for ages of children. Additionally, a distribution 
across economic groups, gender, treatment status (naïve vs. 
on treatment), and length of time on treatment was moni-
tored to ensure representation in the total sample. Partici-
pants were compensated USD $125 (or country equivalent) 
for in-person focus groups or USD $100 (or country equiv-
alent) for telephone interviews as an honorarium regardless 
of recruitment methodology.
To guide the interviews, a semi-structured interview 
guide was designed, based on available research and dis-
cussion with eight clinical experts in individual concept 
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elicitation interviews (in the US, UK, and Germany), to 
elicit the perceived symptoms, burden, and impacts of 
GHD as well as GHD treatment effects on social, physi-
cal, and psychological aspects of daily living. Items and 
probes were designed to be age-specific to accommodate 
child respondents. Questions in the guide were designed 
to be both broad, such as “What is the worst thing about 
having a growth condition and why?” or specific about a 
particular impact, such as “How much does your growth 
condition impact your concentration (focus) or your abil-
ity to pay attention in and out of school?”. For those chil-
dren who had been treated for their GHD, questions asking 
about perceived differences pre- and post-treatment were 
also included. Further, it was expected that young children 
(under approximately age 8 years) would not be able to 
complete a PRO measure by themselves [10] and that a par-
ent ObsRO measure, and not a proxy measure (where the 
reporter responds to what they think or perceive about the 
child), would be needed. Therefore, it was critical for the 
parents to report only actual and not perceived or presumed 
impacts on the child. In order to facilitate observer rather 
than proxy reports, parents were instructed to answer ques-
tions about what they had themselves actually witnessed or 
been told about by another person as having witnessed. To 
ensure this was the case, follow-up questions for impacts 
reported by parents asked the parents to report concrete 
examples of what they had seen or been told that lead them 
to report on the impact.
Trained individuals with backgrounds in qualitative 
interviewing conducted all interviews, and the interviews 
were conducted in the native language of the host country. 
The individual child and parent/guardian telephone inter-
views were 60–75 min long and the in-person focus groups 
were two hours long. The interviews and focus groups were 
recorded, transcribed, and translated into English where 
appropriate.
Data were qualitatively analyzed through an adapted 
grounded theory approach, entailing developing and refin-
ing a theory based on concepts derived during the research 
process [11]. Transcripts were analyzed for content by 
theme using Dedoose, version 7.0.21, a qualitative data 
analysis system [12]. A preliminary code list was devel-
oped based upon the interview and focus group guide, and 
codes were added as new themes emerged during transcript 
review. The transcripts were coded in the chronological 
order in which the interviews and focus groups occurred 
and were each reviewed and coded at least three times 
(and often more) to insure accuracy and consistency. These 
themes were then aggregated into larger domains.
Based on the findings from the qualitative analysis, a 
conceptual model of the major and minor disease-specific 
impacts (other than short stature) was developed. To be 
included in the model, the impact needed to be a discrete 
rather than a broad descriptor of the impact (e.g., worry 
rather than general dislike) and could potentially be affected 
by treatment. Major impacts were those reported by 15% or 
more of the study sample and a minor impact if reported 
by less than 10% of the sample. Items that were endorsed 
between 10 and <15% of the sample were individually 
examined and included as major if they were endorsed by 
20% of parents or children, were proximal rather than dis-
tal impacts, not solely related to height, and/or considered 
conceptually important by clinical experts interviewed (for 
concepts that clinicians would be aware of) or in the liter-
ature. All major impacts were confirmed as both relevant 
and important by respondents during the cognitive debrief-
ing interviews (conducted after the item generation was 
completed with an independent sample of parents and chil-
dren). Additionally, there were three impacts that had 15% 
or higher endorsement by the sample, which after review 
and consideration, were categorized as minor. For example, 
“reaching things” was not perceived as a burden as adapta-
tions were readily available.
Results
Sample description
Thirty-nine children and adolescents ages 8 to <13 years 
with GHD and 31 parents of children ages 4 to <13 years 
with GHD participated totaling 70 respondents. Fifty 
respondents (71.4%) were recruited directly from clinical 
contacts, 4 (5.7%) from professional research organization 
patient panels, and 16 (22.9%) from advocacy and support 
organizations. Seven children were aged 8–9 years and 32 
children were aged 10 to <13 years. Of the 31 parents, 19 
were parents of child respondents who participated in the 
study. Parent respondents provided descriptions of 14 chil-
dren between the ages of 4 and <8 years, 8 children ages 
8–9 years, and 12 children ages 10 to <13 years. All data 
collected in Germany were by focus group (4 focus groups, 
19 respondents). However, the broad geographic distribu-
tion of eligible respondents in the UK and US made focus 
groups logistically unfeasible; thus, all data in these coun-
tries were collected from telephone interviews (51 individ-
ual interviews). Three parents were interviewed about two 
of their children with GHD (two in Germany, one in the 
US). Therefore, for analytic purposes, there was an N = 73 
for the number of narrative descriptions of GHD.
Of the GHD descriptions gathered by interview or focus 
group, slightly over half were from respondents in the US 
(n = 40, 54.8%) with additional respondents from Germany 
(n = 21, 28.8%) and the UK (n = 12, 16.4%). Table  1 pre-
sents the breakdown of respondents by country and age of 
child.
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The mean age of GHD diagnosis was 7 years (range 
3–12 years) for the entire sample; however, the average 
age of diagnosis was the lowest in Germany (4.6 years) 
as compared to the UK (7.0 years) and US (9.4 years). 
A majority of children had taken GH therapy (n = 66, 
90.4%) with treatment beginning on average in Ger-
many at a younger age (4.9 years) than in the UK (7.9 
years) or US (9.5 years) due to this earlier age of diagno-
sis. As a result, the average length of time on treatment 
varied considerably with the longest time on treatment 
reported in Germany (43.0 months), followed by the UK 
(7.9 months) and US (6.5 months). Respondents reported 
many additional health conditions; the most frequent 
were ear, nose, and throat (ENT) conditions; lung dis-
eases or other respiratory conditions (including asthma 
and allergies); and mental health conditions (including 
depression and anxiety). Table  2 presents the details on 
the health and demographic characteristics of children 
and parents associated with the 73 narrative descriptions.
Domains and themes generated by telephone interviews 
and focus groups
A total of 71 concepts emerged from all interviews 
and focus groups conducted; 54 of these concepts were 
addressed by participants in both the child and parent/
guardian samples. Thematic saturation was separately 
assessed for the 39 children and 34 parents/guardians in 
the order in which the interview or focus group occurred. 
A total of 55 concepts were discussed during the child 
interviews; after the 18th child interview, 80% of these 
concepts had been discussed, and by the 34th interview, 
95% of these concepts had been covered. A total of 70 
concepts were discussed during the parent/guardian inter-
views; after the 9th parent/guardian interview, 80% of 
these concepts had been discussed, and by the 20th inter-
view, 95% of these concepts had been covered. The four 
disease impact domains identified were Signs and Symp-
toms, Physical Aspects of Daily Life, Social Well-being, 
and Emotional Well-being. The descriptions of sub-
themes by domain are as follows.
Signs and symptoms
Parent and child-provided descriptions of GHD suggest 
that the subjective experience of GHD is variable and 
individualized. Respondents described a range of symp-
toms in addition to short stature (n = 38, 52%) that lead to 
additional impacts in daily, emotional, and social aspects 
of life. Signs and symptoms reported included poor appe-
tite (n = 34, 47%), reduced strength or poor muscle devel-
opment (n = 34, 47%), poor energy levels (n = 25, 34%), 
reduced endurance (n = 22, 30%), poor sleep (n = 22, 
30%), poor focus or concentration (n = 13, 18%), and 
fatigue (n = 11, 15%). Parent and child respondents were 
in close agreement about the two most frequently reported 
symptoms; parents reported poor appetite (n = 22, 65%), 
reduced strength (n = 17, 50%), and reduced endurance 
(n = 14, 41%), while children reported reduced strength 
(n = 17, 44%), poor appetite (n = 12, 31%), poor energy 
(n = 12, 31%), and poor sleep (n = 12, 31%). The variety 
of symptoms and the frequency that respondents denied 
those symptoms they did not experience suggest that 
symptom distribution is variable. For example, approxi-
mately one-third reported a problem with poor energy 
(n = 25, 34%), but approximately one-quarter reported 
poor energy was not a problem for them when asked 
(n = 17, 23%). However, only a very few commented that 
there were no symptoms associated with GHD other than 
small stature (n = 3, 4%), suggesting that most children 
with GHD experience at least some symptoms. Key mod-
ifiers for these symptoms include age of GH treatment 
initiation and duration of treatment with children starting 
treatment earlier or having been on treatment longer hav-
ing fewer impacts.
There were little to no differences in the narrative 
descriptions of signs and symptoms for boy and girl chil-
dren with GHD. However, there were some distinctions in 
reporting by age group. Symptoms were noted at higher 
frequency for children 4 to <8 years including poor appe-
tite, poor strength or muscle development, poor energy, 
reduced endurance, poor focus, and fatigue. Table  3 pre-
sents the breakdown of all subthemes within the Signs and 
Symptoms domain.
Table 1  Summary of parent 
and child participants by 
country and age (years) of child
Country Child age 4 to <8 Child age 8–9 Child age 10 to <13 #GHD Descrip-
tions (N = 73); 
# (%)Child Parent Child Parent Child Parent
Germany – 6 4 4 7 – 21 (28.8)
United Kingdom – 4 1 1 6 – 12 (16.4)
United States – 4 2 3 19 12 40 (54.8)
TOTALS – 14 7 8 32 12 73 (100)
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Physical aspects of daily life
Parent and child-provided descriptions of GHD indi-
cate that there are several aspects of daily life impacted 
by symptoms of GHD. The overarching theme was the 
level of physical activity, which included reduced perfor-
mance in physical activities/sports (n = 43, 59%), reach-
ing things (n = 32, 44%), and limits of what they could 
Table 2  Health and demographic characteristics of children with GHD described in the study
Ethnic identifications were not collected in Germany due to ethics standards in Germany
a n = 52
Demographic characteristics Germany (n = 21) UK (n = 12) US (n = 40) Totals (N = 73)
Age group counts, # (%)
 Age 4 to <8 years 6 (28.6) 4 (33.3) 4 (10.0) 14 (19.2)
 Age 8–9 years 8 (38.1) 2 (16.7) 5 (12.5) 15 (20.5)
 Age 10–12 years 7 (33.3) 6 (50.0) 31 (77.5) 44 (60.3)
Gender, # (%)
 Female 8 (38.1) 4 (33.3) 10 (25.0) 22 (30.1)
 Male 13 (61.9) 8 (66.7) 30 (75.0) 51 (69.9)
Ethnicity, n = 52; # (%)
 White Not  collecteda 10 (83.3) 36 (90.0) 46 (88.5)a
 Persian 1 (8.3) 1 (1.9)a
 Asian 1 (8.3) 1 (1.9)a
 Other 4 (10.0) 4 (7.7)a
Household Income
 Less than USD 20,000 2 (9.5) 1 (8.3) 1 (2.5) 4 (5.5)
 USD 20,001–40,000 2 (9.5) 3 (25.0) 2 (5.0) 7 (9.6)
 USD 40,001–60,000 1 (4.8) 3 (25.0) 5 (12.5) 9 (12.3)
 USD 60,001–80,000 2 (9.5) 1 (8.3) 6 (15.0) 9 (12.3)
 USD 80,001–100,000 4 (19.0) 13 (32.5) 17 (23.3)
 More than USD 100,000 3 (14.3) 1 (8.3) 9 (22.5) 13 (17.8)
 Decline to answer 7 (33.3) 3 (25.0) 4 (10.0) 14 (19.2)
Other prescription medications
 Yes, # (%) 4 (19.0) 2 (16.7) 23 (57.5) 29 (39.7)
Age at diagnosis
 Mean (range) 4.56 (3–8) 7.01 (3–12) 9.36 (3–12) 6.98 (3–12)
Ever taken GHD therapy
 Yes, # (%) 20 (95.2) 11 (91.7) 35 (87.5) 66 (90.4)
Age first started GHD therapy
 Mean (range) 4.87 (4–8) 7.89 (8–12) 9.47 (3–12) 7.41 (3–12)
Duration (months) of GHD Therapy
 Mean (range) 43.0 (1–96) 7.9 (2–12) 6.5 (0.2–16) 17.8 (0.2–96)
Other health conditions
 Arthritis, rheumatic diseases,  musculoskeletal conditions 1 (2.5) 1 (1.4)
 Ear, nose, and throat conditions 4 (19.0) 6 (15.0) 10 (13.7)
 Eye disorders 1 (4.8) 1 (8.3) 2 (2.7)
 Kidney disease, urinary conditions 1 (8.3) 1 (2.5) 2 (2.7)
 Lung disease, respiratory conditions (including allergies and asthma) 2 (9.5) 15 (37.5) 17 (23.3)
 Mental health conditions (including depression and anxiety) 13 (32.5) 13 (17.8)
 Metabolic conditions (including elevated cholesterol) 2 (9.5) 1 (8.3) 1 (2.5) 4 (5.5)
 Stomach, intestinal, gastrointestinal disease 1 (8.3) 1 (1.4)
 Stroke, neurological condition 1 (8.3) 2 (5.0) 3 (4.1)
 Other condition 1 (4.8) 4 (33.3) 4 (10.0) 9 (12.3)
 None 13 (61.9) 6 (50.0) 15 (37.5) 34 (46.6)
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do because of size (n = 14, 19%) (Table 4). Additionally, 
these impacts were often described as improving with 
GHD treatment. Parent and child respondents were in 
agreement about the two biggest impacts: reduced perfor-
mance in physical activities or sports (parent n = 23, 68% 
and child n = 20, 51%) and reaching things (parent n = 16, 
47% and child n = 16, 41%). However, of note, reaching 
things was not perceived as a burden as adaptations were 
readily available. None of the respondents commented 
that there were no daily life physical impacts for children 
with GHD. Key modifiers for these impacts include age 
of treatment initiation and duration of treatment. Children 
who started treatment at a younger age or had been on 
treatment longer had fewer physical impacts.
Descriptions of girl children with GHD included more 
frequent reports of reduced performance in physical activi-
ties or sports. Parent-provided descriptions of children 
between the ages of 4 and <8 years emphasized difficulty 
reaching things with greater frequency than the 8–9 years 
or 10 to <13 years age groups.
Social Well‑Being
The social impacts of GHD reported by the respondents 
were often a result of the child’s visibly smaller size and 
Table 3  Sign and Symptoms 






N = 73 % N = 39 % N = 34 %
Smaller or smallest among peers 38 52 13 33 25 74
Poor appetite 34 47 12 31 22 65
No problem with appetite 3 4 0 0 3 9
Reduced strength/poor muscle development 34 47 17 44 17 50
No problem with strength 6 8 0 0 6 18
Poor energy 25 34 12 31 13 38
No problem with energy 17 23 7 18 10 29
Reduced endurance 22 30 8 21 14 41
Poor sleep 22 30 12 31 10 29
Poor focus or concentration 13 18 5 13 8 24
No problem with focus 15 21 10 26 5 15
Fatigue or tiredness 11 15 3 8 8 24
Impaired immune system 4 5 1 3 3 9
No symptoms noted 3 4 0 0 3 9
Table 4  Physical aspects of 






N = 73 % N = 39 % N = 34 %
Reduced performance in physical activities/sports 43 59 20 51 23 68
No problem with physical activities/sports 18 25 14 36 4 12
Reaching things 32 44 16 41 16 47
No problem reaching things 5 7 4 10 1 3
Limits/not allowed to do things because of size 14 19 5 13 9 26
Low Weight or Underweight 11 15 3 8 8 24
Overweight 3 4 1 3 2 6
Additional difficulty with daily activities 9 12 1 3 8 24
Difficulty with climbing stairs 8 11 1 3 7 21
Difficulty with toileting 5 7 0 0 5 15
Needs booster seats longer 1 1 0 0 1 3
Delayed puberty 2 3 0 0 2 6
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often contributed to the emotional impacts of the condition. 
These included being mistaken for a younger age (n = 41, 
56%), teasing or bullying (n = 35, 48%), being treated dif-
ferently than peers by adults (n = 20, 27%) or other children 
(n = 20, 27%), social unease or not fitting in (n = 19, 26%), 
choosing not to participate or holding back from participa-
tion (n = 18, 25%), and exclusion from activities/playing 
(n = 7, 10%) (Table 5). For many of the respondents, it was 
the repetition of a negative social experience that contrib-
uted to emotional impacts. The most frequent concern for 
many parent and child respondents was the consistent pat-
tern of being mistaken for younger and feeling underesti-
mated, which resulted in differential treatment by adults 
and other children. Similarly, to previous impact domains, 
there was variability in these experiences. Approximately 
one-fifth of the sample (n = 16, 22%) reported that there 
were no social impacts associated with GHD. An impor-
tant mediating influence that modulated the negative social 
experience was social support from family, friends, or 
teachers and school systems. Social support was reported 
by approximately a quarter of the sample (n = 19, 26%). 
And although verbal teasing was a strong concern, many 
reported that they or their child had not endured teasing 
(n = 30, 41%) and some felt that children with GHD were 
not treated differently by other children (n = 13, 18%).
Although there was little difference between boy and girl 
children around the theme of verbal teasing, all the descrip-
tions of bullying, defined as having a physical aspect of 
pushing or fighting, were reported for boy children. Boys 
were also more frequently described as having social 
unease or difficulty fitting in with their peers. However, 
boys were more frequently described as experiencing social 
support than girls with GHD. Finally, girls were more fre-
quently reported as being treated differently by other chil-
dren and having clothing size and age appropriateness of 
clothing concerns.
Table 5  Social Well-Being 








N = 73 % N = 39 % N = 34 %
Being mistaken for younger 41 56 17 44 24 71
Teasing or bullying 35 48 14 36 21 62
Teasing but it feels okay 4 5 2 5 2 6
No experience with teasing 30 41 24 62 6 18
No experience with bullying 6 8 6 15 0 0
Treated differently than peers by adults 20 27 4 10 16 47
Treated differently by other children 20 27 5 13 13 38
Not treated differently by other children 13 18 9 23 4 12
Social unease/Not fitting in 19 26 6 15 13 38
No problem with social unease 5 7 1 3 4 12
Experiences social support 19 26 8 21 11 32
Family support 14 19 7 18 7 21
Friend support 5 7 5 13 0 0
Teacher/school support 4 5 0 0 4 12
Clothing/wearing clothes typically worn by younger children 19 26 4 10 15 44
Choosing not to participate/holding back or withdrawing from 
participation
18 25 4 10 14 41
No problem with participation 6 8 4 10 2 6
No social impact 16 22 8 21 8 24
Tension between siblings due to sibling sizes 10 14 3 8 7 21
No problem between siblings 5 7 4 10 1 3
School Impacts 10 14 3 8 7 21
Missed school time/medical 8 11 2 5 6 18
Held back a year 2 3 1 3 1 3
Excluded from activities/playing 7 10 0 0 7 21
No problem with exclusion 7 10 4 10 3 9
Does not tell others about GHD 7 10 5 13 2 6
Prefers to play with younger children 6 8 1 3 5 15
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There were some distinctions in reporting by age group. 
Verbal teasing, being treated differently than peers by 
adults and other children, choosing not to participate or 
withdrawal from activities, and concern about clothing size 
or age appropriateness of clothing were noted at higher fre-
quency for children between the ages of 4 to <8 years.
Emotional Well‑Being
Parents and children identified a number of emotional 
impacts, including generally disliking or feeling bothered 
by their own height (n = 46, 63%) and worry (n = 36, 49%) 
(Table  6). Children with GHD were reported to worry 
about being or feeling different (n = 28, 38%), worry about 
growing (n = 15, 21%), or worry about how they will be 
treated socially (n = 7, 10%). Child and adult respondents 
also reported poor self-confidence (n = 24, 33%), sad or 
hurt feelings (n = 15, 21%), embarrassment (n = 13, 18%), 
anger (n = 13, 18%), annoyance (n = 13, 18%), frustration 
(n = 11, 15%), feeling upset (n = 10, 14%), and feeling nerv-
ous or anxious (n = 9, 12%). Approximately one-fifth of the 
sample (n = 15, 21%) reported that there were no emotional 
impacts associated with GHD.
Many of the emotional impacts described resulted from 
social impacts of GHD or being bothered by their height or 
size. Child and parent respondents reported most frequently 
on the same emotional impacts but, not surprisingly, chil-
dren were less willing or able to report these negative emo-
tional impacts than were parent respondents. For example, 
worries about being/feeling different were reported by 9 
Table 6  Emotional Well-Being 






N = 73 % N = 39 % N = 34 %
Dislikes/is bothered by height or size 46 63 25 64 21 62
Is not bothered by height or size 25 34 11 28 14 41
Worry 36 49 14 36 22 65
Worries about being/feeling different 28 38 9 23 19 56
Worries about growing 15 21 6 15 9 26
Worries about social treatment 7 10 5 13 2 6
Poor self-confidence 24 33 5 13 19 56
No problem with self-confidence 8 11 0 0 8 24
Sad or hurt feelings 15 21 7 18 8 24
No emotional impact 15 21 6 15 9 26
Embarrassment 13 18 7 18 6 18
No problem with embarrassment 18 25 12 31 6 18
Anger 13 18 2 5 11 32
No problem with anger 2 3 1 3 1 3
Annoyance 13 18 4 10 9 26
Compensation strategies for small size 13 18 0 0 13 38
Big personality 11 15 0 0 11 32
Verbal strategies/negotiation 2 3 0 0 2 6
Frustration 11 15 2 5 9 26
Upset 10 14 2 5 8 24
Nervous or anxious 9 12 2 5 7 21
Poor self-image 5 7 1 3 4 12
Positive emotional impacts
Perceives some benefit to small size 17 23 13 33 3 9
Likes being small in size 12 16 8 21 4 12
Acceptance of GHD 12 16 8 21 4 12
Emotional impacts on Parents
Worry 16 22 0 0 16 47
Anger or frustration 13 18 0 0 13 38
Relief or content when a diagnosis was made 10 14 0 0 10 29
Pressure or tension, feeling stressed 4 5 0 0 4 12
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(23%) children and 19 (56%) parents and poor self-confi-
dence by 5 (13%) children and 19 (56%) parents. Having a 
sibling or other family members with GHD was an impor-
tant modifier for emotional impacts, as was the experience 
of positive social support from family, friends, and peers.
There were positive emotional impacts reported as 
well. Many of the child respondents were asked if they 
could identify benefits to being small and approximately 
one-quarter of the total sample (n = 17, 23% total sample 
and n = 13, 33% of the child respondents) could report 
some benefits. These included the ability to fit into small 
spaces, lower fees for activities because they looked to be a 
younger age, and the agility to move faster or more flexibly 
than others. Some child and parent respondents reported 
that the child liked being small in size or stature (n = 12, 
16%) and some reported that the child had accepted the 
diagnosis of GHD (n = 12, 16%).
Finally, parents reported that they experienced emotional 
impacts from their child’s GHD. Among parents, nearly 
half reported worry for their child (n = 16, 47%), anger or 
frustration over the reactions of others about their child’s 
size (n = 13, 38%), relief or contentment when a diagnosis 
was made (n = 10, 29%), and pressure or tension in parent-
ing and managing treatment for their children (n = 4, 12%).
There were some distinctions in reporting by age group. 
Dislike or feeling bothered by one’s height, worry in gen-
eral and worry specifically about growth or growing was 
noted at higher frequency for boys than for girls. Feeling 
hurt or upset, annoyance, and frustration were noted at 
higher frequency for girls than for boys. Worry about being 
different from others and frustration were reported at higher 
frequency for children between the ages 4 and <8 years.
Conceptual and theoretical model
The model presents the major and minor proximal and 
distal impacts of GHD along with key modifiers that can 
impact the individual experience of the disease (Fig. 1). For 
a major domain to be included in the model, it had to be 
endorsed by both children and parents as important and rel-
evant. Table 7 presents the parent and child quotes for each 
major impact.
Discussion
This qualitative study provides evidence that the experi-
ence of GHD is multi-faceted and that it impacts multiple 
aspects of daily life for children with the condition. With 
few exceptions, the experiences are negative and result in 
substantial disease burden. Their symptoms span a wide 
range and are often variable and individualized beyond 
the most basic effect of GHD: small stature and reduced 
growth. Signs and symptoms limit physical aspects of daily 
life, thus making them even more visible as different from 
their peers. This is noticed by their peers and by adults as 
well. It is apparent that this visibility may lead to further 
difficulties, resulting in differential social treatment that 
contributes either as a proximal impact or as a more dis-
tal negative emotional impact. As there are many causes of 
GHD, including prior illness or concussions in addition to 
genetic susceptibility, it is not surprising that this variabil-
ity of experience exists for these children.
Some of the physical impacts of daily life such as “reach-
ing up to get things,” social impacts such as “people think-
ing you are younger than you are,” and emotional impacts 
such as “worried about growing” link directly to the small 
stature associated with GHD, its related symptoms, and the 
inability for children with GHD to reach physical devel-
opmental milestones expected of children their age. With 
growth hormone replacement treatment, many children 
with GHD can grow to normal height [3] and improvement 
in self-esteem, emotional well-being, and mood in children 
with GHD have been shown [13, 14]. If left untreated, or 
if GHD develops late in childhood, the condition can con-
tribute to shorter-than-average height and delayed puberty 
[3, 15]. Thus, beginning treatment at an early age could be 
an important modifier in the experience of GHD and its 
impacts by facilitating growth and physical ability.
This study also has clinical implications for physicians 
and their patients. Understanding the considerable impact 
of GHD on children can improve communications between 
parents, their children, and physicians. Through an under-
standing of the consequences of GHD, physicians and par-
ents can better support children with the condition, advo-
cating not only for early treatment but also for a reduction 
in the social circumstances of teasing, bullying, and exclu-
sion that cause so much harm.
All impacts were found to be relevant to both younger 
and older children; however, some differences in level of 
endorsement of impacts for older versus younger children 
were found. The difference in level of endorsement may 
have been influenced by the fact that there were no children 
under the age of 8 who were interviewed and provided self-
report, and therefore, impacts reported for younger chil-
dren were solely reliant upon parents’ observations. Future 
quantitative research would be helpful to further exam-
ine this issue. Finally, the child focus groups in Germany 
seemed to have a strong cohort effect with little diversity in 
opinion or experience. While it may be true that the expe-
rience of GHD occurs uniformly across these individuals, 
it may also be true that children, when gathered in groups, 
tend towards agreement rather than disagreement with one 
another and that the individual interviews conducted in the 
United Kingdom and United States were more able to elicit 
a wider range of experience.
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As with all research, there are some limitations to this 
study. First, although this study included reports from 73 
child and parent-provided descriptions of GHD experi-
ence (a large sample size for qualitative research), these 
findings still may not be generalizable to all children with 
GHD in other countries or ethnic groups. Further, it is 
possible that volunteers for participation in research form 
a unique population that results in a sample that may not 
be representative of all children with GHD or their par-
ents. However, given that recruitment employed three 
different methodologies, the sample pool was potentially 
broadened. Finally, quantitative research that investigates 
the relationship between early treatment and reduced 
impacts is needed.







Major PHYSICAL IMPACT Minor
• Level of physical activity
• Reduced/limited performance in sports/activities
• Unable to keep up/not allowed to do sports/activities
•
Major SOCIAL WELL-BEING Minor
• Not fitting in/level of ease with peers
• Mistaken for younger than age
• Treated differently by adults
• Teasing/name calling
• Bullying
• Treated differently by other children
• Left out/excluded from activities





• Impaired immune system
Major
• Reaching things
• Difficulty climbing stairs
• Difficulty with toileting
• Clothing/finding age appropriate clothes and shoes
• Choosing to play with younger or smaller children
• Tension between siblings due to small size/sibling 
size



















• Low weight or underweight
• Delayed puberty








• Acceptance of limitations
• Number/age/size of siblings
• Age at treatment start
• Duration of treatment

















Fig. 1  Preliminary disease burden of CGHD theoretical model
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Table 7  Selected Quotes for Major Themes
Theme/subtheme Selected quote
Signs and Symptoms
 Poor appetite Parent: Her appetite has doubled, so now she takes seconds and thirds at dinner and 
eats quickly, is hungry when she sits down. That aspect of her is a whole new child
Child: I’m eating more. I used to not be eating all of my plate, but now I’m eating 
most of it
 Reduced strength or poor muscle development Parent: In swimming she was lacking the ability to keep up with her peers in her age 
group because she was small, her muscle tone was small
Child: Like a lot of kids could like—because they were tall ones, they were a little 
bit stronger than me and they could do more things like more pull‑ups than me, but 
I’ve been getting stronger
 Poor energy and/or reduced endurance Parent: The biggest impact for him…he isn’t as powerful as others. He is ambitious, 
but he is tired very fast when he is doing sports. He isn’t as powerful
Child: Well, before I started the treatment I couldn’t really like run as fast as I am 
now. And it was like I ran out of breath in short periods of time, rather than keep‑
ing—keep running when I was in breath when I was out of breath
 Poor sleep Parent: She has never been a good sleeper, but she used to wake up early in the 
morning, couldn’t go back to sleep, had circles under her eyes
Child: Yes, I used to never sleep good. Like I used to wake up in the middle of the 
night and now I sleep better
 Poor focus/concentration Parent: Now she can actually sit through a board game or an arts and crafts kind of 
thing
Child: When I’m sitting in school and we’re reviewing a test, I’m more focused and I 
really want to correct everything and really concentrate
 Fatigue or tiredness Parent: He sometimes just lay down, because he was totally exhausted after a few 
hours without having done something special. He didn’t do any sports or ride a 
bike or whatever, but he just got up, had breakfast, went to the kindergarten, and 
was totally exhausted by that
Child: I just like, sometimes just can’t stay awake. I get really tired sometimes
Physical aspects of daily life
 Reduced performance in physical activities/sports Parent: Because the year before, we’d noticed – I mean he virtually came last in 
everything whereas this year when he did his sports day, then he was up in the 
middle of the pack
Child: I mean, it would be really hard to, like if we were playing tag, I would feel 
myself like I wouldn’t run as fast as I really thought I wanted to, and it really 
bummed me out because I never wanted to play. I mean I played, but it wasn’t 
really all that enjoyable
 Limits/not allowed to do things because of size Parent: I purposely didn’t let him play basketball because of his height
Child: Like before that when I was younger, I was not able to ride all of the rides. I 
never went to the amusement park with some of my friends
Social Well‑Being
 Being mistaken for younger Parent: You know mostly if we go out to a restaurant they always want to give him 
the kids menu. You know I don’t want the kids menu… He’ll say, “No thank you” 
or “may I have a regular menu”, but I know it bothers him. He says he doesn’t like 
it, and his older brother went through it too
Child: Like everybody would ask who’s older and I would always say, “Me.” Then 
they would say, “Is she taller?” Yeah, because she looks older since she’s taller 
than me… At first I didn’t mind, but then everywhere they started asking. Then it 
started bugging me. And then I was just tired of it
 Teasing or bullying Parent: Yeah, well he has a tendency, he keeps things a little bit inside, so he’ll come 
home from school in a rotten mood, yelling, crying, and you have no idea why 
and sometimes it’s at bedtime or sometimes it’s a week later that I find out what 
happened and somebody said something. You’re too little to play this or somebody 
made a comment about this or… But if he gets upset, that’s kind of like he won’t 
necessarily tell you right then and there
Child: I was walking to the bus stop yesterday and then this boy that I didn’t even 
know that was in a car rolled down his window and shouted “you midget!”
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Table 7  (continued)
Theme/subtheme Selected quote
 Treated differently than peers by adults Parent: That she was constantly confronted with the fact that people thought that she 
was younger. Her physical and mental abilities did not match the way she looked 
like. She was constantly confronted with that discrepancy
Child: Well they’d talk to me like, hmm… or they would talk to me like if I were nine 
or younger like using not so big words
 Treated differently by other children Parent: I’ve observed some of the kids on his baseball team you know patting him on 
the head and doing that sort of thing
Child: People who have just met me, treat me as like I’m younger than… Like if 
they’re not in the same age as me and I know that and they don’t know that ‑ ‑ they 
typically don’t know that I’m the same age as them just because I’m shorter than 
them
 Social unease/not fitting in Parent: I knew he just felt very, very uncomfortable in those social situations, and I 
‑ ‑ and I guess at that time I didn’t realize it was that strongly tied to his height, but 
now looking back, it absolutely was. Absolutely that was the whole ‑ ‑ that was the 
whole reason, there was no other reason
Child: I used to be ‑ ‑ I think it ‑ ‑ I used to be like always like the one that wasn’t fit 
in with everyone else, and I think the growth hormone helps me a lot with that one
 Choosing not to participate/withdrawing or holding back Parent: Sometimes when other people start off running, you see he’ll run just a cou‑
ple paces and then he’ll stop. This… Say, “Oh, well, I can’t keep up with them.”
Child: Like I don’t want to join in because that’s the part where I’m scared most 
people will make fun of me
 Left out/excluded from activities Parent: My son is not accepted by other children of the same age as being a play pal 
for them. […] The kindergarten people told me that he doesn’t play with them at 
all because they don’t see him
Parent: My son started to suffer from the fact that he was so short. The older chil‑
dren didn’t want to play with him anymore. They didn’t want to play with the little 
ones. And he couldn’t play with the real little ones because the age gap was too 
big. […] It was difficult for him
Emotional Well‑Being
 Worry Parent: My son was already worried. He is seven now, and during the last six 
months he was really worried why he didn’t grow anymore
Child: I was always smaller than the other kids, but like last year I wasn’t growing 
at all and I was getting kind of worried
 Poor self-confidence Parent: He never said anything specifically about, oh I’m short and boo‑hoo, woe 
is me, but it was just, you just knew that’s what it was. I can’t even explain. I can’t 
even explain how you would know that, but as a parent you can just tell that he had 
no ‑ ‑ why would you have no confidence in yourself? People who have no confi‑
dence in themselves are you know people who have something that makes them 
feel uncomfortable about themselves… you can just see it in a child. They behave 
in a different manner. They’re quiet; they’re not very social, and you know he was 
definitely that kid
Child: Like I didn’t feel like good about myself. Like I would always be short for 
the rest of my life, but I’m feeling better about myself and stuff ‑ like feeling better 
about myself
 Sad or hurt feelings Parent: Lisa sat in the corner, crying, because somebody had said: “hey, little one”
Child: Could be a little sad because I don’t like want to be short; like you know I 
don’t want to have that condition at all, yeah
 Embarrassment Parent: So I mean that’s just, like you could just see it in his face. Like that was like 
a slap in the face. You might as well have just punched him, because that’s how 
he felt. You know he just had to stand there while everybody else was just doing 
that one, because he couldn’t do it. And I was like ‑ ‑ I came home and I said to 
my husband my God we got to get him out of that class. You know. Now he doesn’t 
want to do it anymore
Child [referring to size]: I just felt embarrassed
 Anger Parent: Yeah, even last summer. There was still one ride he couldn’t ride. And we 
didn’t even talk about it. He would get so mad
Child: I feel kind of sad and mad my body doesn’t work right, but I’m kind of happy 
that I can grow more than I would have if I didn’t do it
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Conclusion
This study demonstrates that the burden of GHD in chil-
dren and adolescents is considerable and not limited to 
short stature. GHD includes multiple symptoms for some 
patients, including poor appetite, poor strength or muscle 
development, poor energy levels, reduced endurance, poor 
sleep, problems with focus or concentration, and fatigue. 
These symptoms, in combination with visible difference in 
size compared to peers, lead to physical limitations impact-
ing daily life, and social, or emotional impacts. The sever-
ity of GHD impact on children and adolescents appears 
to be variable and individualized, but these data indicate 
that early identification and treatment may lead to fewer 
impacts. There is also a need for further research in these 
aspects of care for children with GHD.
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